Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Drug Pricing Comments Mainly Stick To Script

Executive Summary

With only one new proposal, brand industry association seems to banking on strength of past policy positions as Trump's drug pricing blueprint moves towards implementation stage.

You may also be interested in...



FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs

FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.

Beyond Rebates: PhRMA Wants HHS To ‘De-Link’ Supply Chain Compensation From List Price

Focus should not be limited to rebates in Medicare Part D, manufacturers advise in comments on HHS drug pricing blueprint. Pharmacy benefit managers raise anti-trust issues with shift to upfront discounts.

Congressional Action On Drug Pricing Blueprint Likely To Be Modest

Senate Health, Education, Labor and Pensions Committee Chair Lamar Alexander noted panel's lack of consensus on drug pricing policies advanced by the Trump Administration during June 12 hearing.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS123515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel